Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials
Harold R Collard, Eric Yow, Luca Richeldi, Kevin J Anstrom, Craig Glazer, IPFnet investigators, M Schwarz, D A Zisman, G Hunninghake, J Chapman, M Olman, S Lubell, L D Morrison, M P Steele, T Haram, J Roman, R Perez, T Perez, J H Ryu, J P Utz, A H Limper, C E Daniels, K Meiras, S Walsh, K K Brown, M Schwarz, C Bair, D Kervitsky, J A Lasky, S Ditta, J deAndrade, V J Thannickal, M Stewart, D A Zisman, J Lynch, E Calahan, P Lopez, T E King Jr, H R Collard, J A Golden, P J Wolters, R Jeffrey, I Noth, D K Hogarth, N Sandbo, M E Strek, S R White, C Brown, I Garic, S Maleckar, F J Martinez, K R Flaherty, M Han, B Moore, G B Toews, D Dahlgren, G Raghu, J Hayes, M Snyder, J E Loyd, L Lancaster, W Lawson, R Greer, W Mason, R J Kaner, V Monroy, M Wang, D A Lynch, T Colby, K J Anstrom, R C Becker, E L Eisenstein, N R MacIntyre, L D Morrison, J Rochon, M P Steele, J S Sundy, L Davidson-Ray, P Dignacco, R Edwards, R Anderson, R Beci, S Calvert, K Cain, T Gentry-Bumpass, D Hill, M Ingham, E Kagan, J Kaur, C Matti, J McClelland, A Meredith, T Nguyen, J Pesarchick, R S Roberts, W Tate, T Thomas, J Walker, D Whelan, J Winsor, Q Yang, E Yow, H Y Reynolds, X Tian, J Kiley, Harold R Collard, Eric Yow, Luca Richeldi, Kevin J Anstrom, Craig Glazer, IPFnet investigators, M Schwarz, D A Zisman, G Hunninghake, J Chapman, M Olman, S Lubell, L D Morrison, M P Steele, T Haram, J Roman, R Perez, T Perez, J H Ryu, J P Utz, A H Limper, C E Daniels, K Meiras, S Walsh, K K Brown, M Schwarz, C Bair, D Kervitsky, J A Lasky, S Ditta, J deAndrade, V J Thannickal, M Stewart, D A Zisman, J Lynch, E Calahan, P Lopez, T E King Jr, H R Collard, J A Golden, P J Wolters, R Jeffrey, I Noth, D K Hogarth, N Sandbo, M E Strek, S R White, C Brown, I Garic, S Maleckar, F J Martinez, K R Flaherty, M Han, B Moore, G B Toews, D Dahlgren, G Raghu, J Hayes, M Snyder, J E Loyd, L Lancaster, W Lawson, R Greer, W Mason, R J Kaner, V Monroy, M Wang, D A Lynch, T Colby, K J Anstrom, R C Becker, E L Eisenstein, N R MacIntyre, L D Morrison, J Rochon, M P Steele, J S Sundy, L Davidson-Ray, P Dignacco, R Edwards, R Anderson, R Beci, S Calvert, K Cain, T Gentry-Bumpass, D Hill, M Ingham, E Kagan, J Kaur, C Matti, J McClelland, A Meredith, T Nguyen, J Pesarchick, R S Roberts, W Tate, T Thomas, J Walker, D Whelan, J Winsor, Q Yang, E Yow, H Y Reynolds, X Tian, J Kiley
Abstract
Background: Acute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure.
Methods: Three investigators retrospectively reviewed subjects enrolled in the Sildenafil Trial of Exercise Performance in IPF who experienced a respiratory serious adverse event during the course of the study. Events were classified as definite acute exacerbation, suspected acute exacerbation, or other, according to established criteria.
Results: Thirty-five events were identified. Four were classified as definite acute exacerbation, fourteen as suspected acute exacerbation, and seventeen as other. Definite and suspected acute exacerbations were clinically indistinguishable. Both were most common in the winter and spring months and were associated with a high risk of disease progression and short-term mortality.
Conclusions: In this study one half of respiratory serious adverse events were attributed to definite or suspected acute exacerbations. Suspected acute exacerbations are clinically indistinguishable from definite acute exacerbations and represent clinically meaningful events. Clinical trialists should consider capturing both definite and suspected acute exacerbations as outcome measures.
Figures
References
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA. et official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. doi: 10.1164/rccm.2009-040GL.
- Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–440. doi: 10.1164/rccm.201006-0894CI.
- Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3:285–292. doi: 10.1513/pats.200601-005TK.
- Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA. et al.Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–643. doi: 10.1164/rccm.200703-463PP.
- Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:356–363. doi: 10.1183/09031936.00159709.
- Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J. et al.Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–1769. doi: 10.1016/S0140-6736(11)60405-4.
- King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:92–99. doi: 10.1164/rccm.201011-1874OC.
- Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A. et al.Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–829. doi: 10.1183/09031936.00005209.
- Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:620–628.
- American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. international consensus statement. American thoracic Society (ATS), and the European respiratory society (ERS) Am J Respir Crit Care Med. 2000;161:646–664.
- King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75–81. doi: 10.1164/rccm.200705-732OC.
- King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M. et al.Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374:222–228. doi: 10.1016/S0140-6736(09)60551-1.
- Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G. et al.Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–1087. doi: 10.1056/NEJMoa1103690.
- Olson AL, Swigris JJ, Raghu G, Brown KK. Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest. 2009;136:16–22. doi: 10.1378/chest.08-0703.
- Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, Huh JW, Taniguchi H, Chiu C, Boushey H. et al.Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:1698–1702. doi: 10.1164/rccm.201010-1752OC.
- Huie TJ, Olson AL, Cosgrove GP, Janssen WJ, Lara AR, Lynch DA, Groshong SD, Moss M, Schwarz MI, Brown KK, Frankel SK. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology. 2010;15:909–917. doi: 10.1111/j.1440-1843.2010.01774.x.
Source: PubMed